Tenofovir vs.entecavir in reducing hepatocellular carcinoma risk in patients with chronic HBV infection?-Still an unsolved question  

作　　者：Hyun-Seok Kim Hashem B.El-Serag 

机构地区：[1]Section of Gastroenterology and Hepatology,Baylor College of Medicine,Houston,TX,USA [2]U.S.Michael E.DeBakey Veterans Affairs Medical Center,Houston,TX,USA

出　　处：《Hepatobiliary Surgery and Nutrition》2021年第1期119-122,共4页肝胆外科与营养（英文）

摘　　要：Chronic hepatitis B virus(CHB)infection affects approximately 250 million persons worldwide(1).CHB is a major risk factor for liver failure,cirrhosis,and hepatocellular carcinoma(HCC),accounting for 45-55%of HCC cases(1).The incidence rates of HCC among CHB patients are 0.02-0.2 per 100 person-years in inactive carriers,0.3-0.6 per 100 person-years in those without cirrhosis,and 2.2-3.7 per 100 person-years for those with compensated cirrhosis(2).

关 键 词：PATIENTS HEPATOCELLULAR infection 

分 类 号：R73[医药卫生—肿瘤]